Short Interest in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Drops By 17.3%

Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,440,000 shares, a decrease of 17.3% from the October 31st total of 2,950,000 shares. Based on an average daily volume of 562,900 shares, the short-interest ratio is currently 4.3 days.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $6.86 on Monday. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72. The company has a market cap of $374.76 million, a price-to-earnings ratio of 9.66 and a beta of 0.89. The stock has a 50 day simple moving average of $6.51 and a 200-day simple moving average of $7.29.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same period last year, the firm posted ($0.59) earnings per share. Analysts anticipate that Voyager Therapeutics will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics during the 3rd quarter valued at about $74,000. SG Americas Securities LLC acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at about $85,000. Victory Capital Management Inc. lifted its stake in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth approximately $128,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on VYGR shares. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 18th. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $17.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.